| __timestamp | ACADIA Pharmaceuticals Inc. | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 60602000 | 79838000 |
| Thursday, January 1, 2015 | 76369000 | 121816000 |
| Friday, January 1, 2016 | 4406000 | 117633000 |
| Sunday, January 1, 2017 | 13060000 | 4577000 |
| Monday, January 1, 2018 | 18330000 | 12670000 |
| Tuesday, January 1, 2019 | 19598000 | 12135000 |
| Wednesday, January 1, 2020 | 20550000 | 18942000 |
| Friday, January 1, 2021 | 19141000 | 32328000 |
| Saturday, January 1, 2022 | 10166000 | 44678000 |
| Sunday, January 1, 2023 | 45731000 | 65486000 |
Cracking the code
In the dynamic world of biopharmaceuticals, understanding cost structures is crucial for investors and stakeholders. This analysis focuses on the cost of revenue trends for PTC Therapeutics, Inc. and ACADIA Pharmaceuticals Inc. from 2014 to 2023. Over this period, PTC Therapeutics consistently reported higher costs, peaking in 2015 with a 52% increase compared to 2014. Meanwhile, ACADIA Pharmaceuticals experienced a significant fluctuation, with a notable dip in 2016, where costs plummeted by 94% from the previous year. By 2023, both companies showed a resurgence, with ACADIA's costs increasing by 350% from 2022, while PTC's costs rose by 47%. These trends highlight the volatile nature of the industry, driven by factors such as R&D investments and market dynamics. Investors should consider these patterns when evaluating potential growth and profitability in the biopharmaceutical sector.
Cost of Revenue Trends: Pfizer Inc. vs PTC Therapeutics, Inc.
Cost of Revenue Trends: United Therapeutics Corporation vs PTC Therapeutics, Inc.
Cost Insights: Breaking Down Incyte Corporation and ACADIA Pharmaceuticals Inc.'s Expenses
BioMarin Pharmaceutical Inc. vs ACADIA Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Sarepta Therapeutics, Inc. and ACADIA Pharmaceuticals Inc.
Cost of Revenue Comparison: Jazz Pharmaceuticals plc vs ACADIA Pharmaceuticals Inc.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and PTC Therapeutics, Inc.
Cost of Revenue Trends: Grifols, S.A. vs ACADIA Pharmaceuticals Inc.
Cost Insights: Breaking Down PTC Therapeutics, Inc. and Perrigo Company plc's Expenses
Cost of Revenue: Key Insights for PTC Therapeutics, Inc. and Dyne Therapeutics, Inc.
ACADIA Pharmaceuticals Inc. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: ACADIA Pharmaceuticals Inc. vs Evotec SE